Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery

Andrews, Timothy E.; Wang, Dan; Harki, Daniel A.

doi:10.1007/s13346-012-0075-1

Cited by 18 publications

(12 citation statements)

References 228 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following the emergence of CSC hypothesis and its potential roles in tumor progression, metastasis, recurrence, and resistance to treatment, many efforts have been devoted to explore the implication of CSCs in prediction, prognosis, and treatment of various kinds of tumors including colorectal cancer [4]. A more recent interest has focused on circulating CSC (CCSC) markers based on the fact that PB is a suitable sample for investigating tumor markers as it benefits from noninvasiveness, simplicity of sampling, and affordability [52,53] subpopulation as a potential CCSC marker in PB of patient suffering from hepatocellular carcinoma (HCC) and revealed that patients with CCSC ≤0.01 % showed significantly more favorable prognosis than those with CCSC >0.01 % [55].…”

Section: Discussionmentioning

confidence: 99%

“…In spite of several available diagnostic procedures for early detection and monitoring of CRC including fecal occult blood test (FOBT) and carcinoembryonic antigen (CEA), finding more reliable, sensitive, and specific markers is still considered as a primary concern for prognostic and diagnostic purposes [3]. Recently, a great deal of investigations has focused on cancer stem cell (CSC) and its markers in tumor diagnosis, monitoring, and therapy [4][5][6]. According to CSC hypothesis, a minority population of cancer cells defined as CSCs is responsible for tumor initiation, metastasis, recurrence, and drug resistance [7][8][9][10][11], suggesting that application of CSC markers is a more efficient strategy for diagnosis, monitoring, and treatment of tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients

et al. 2015

View full text Add to dashboard Cite

Cancer stem cell (CSC) markers have attracted considerable attention in tumor diagnostic, prognostic, and therapeutic implications. Detection of cancer stem cells in circulating blood using cancer stem cell markers has received remarkable attention recently. In this study, we aimed to investigate the messenger RNA (mRNA) expression level of Lgr5 and DCLK1 as most proposed colorectal CSC markers in blood circulation also determine the subsequent association to patients' clinical and pathological findings. Peripheral blood mononuclear cells (PBMCs) of 58 patients with colorectal cancer at stage I-IV with 33 out of 58 patients undergoing preoperative chemoradiotherapy (CRT), as well as 58 healthy controls have been isolated and the extracted RNAs were analyzed using real-time PCR. The mRNA expression pattern of CSC markers of patients and controls was compared using ΔΔCt method. The expression level of Lgr5 was significantly higher in colorectal cancer (CRC) patients comparing to healthy group (4.8-fold change, p < 0.001). Also there was a significant increase in expression level of Lgr5 in patients at stages III and IV comparing to stages I and II (p = 0.031) and higher grades (p = 0.039) of CRC. The expression of DCLK1 was also elevated in patients significantly (2.7-fold change, p < 0.001) and the related expression was increased by increasing disease stage (p = 0.025). Combination of DCLK1 and Lgr5 markers was analyzed by logistic regression and proved to be a slightly better marker compared to each marker alone. Interestingly the DCLK1 expression level was significantly higher in patients undergoing preoperative CRT (p = 0.041); however, no association to neoadjuvant CRT was observed for Lgr5. Considering the over-expression of DCLK1 and Lgr5 in circulating blood of CRC patients comparing to controls, our results might emphasize on the presence of CSCs in blood of these patients which might be attributed to their clinical and pathological characteristics and may lead to apply in future clinical implications. Moreover, the higher expression level of DCLK1 in patients undergoing CRT can propose it as a more relevant candidate among CSC markers comparing to Lgr5 for CRC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In addition, the lung cancer cells, also predominantly possess CD 44 + cells which have been shown to be able to form tumors that resemble the primary tumor . Although most of the solid tumor's express CD 44 surface marker, there are other cell surface marker's such as CD 24, CD133, CD 176, which are differentially expressed among CSC of diverse origin . CD 44 is an important cell surface marker associated with cellular adhesion and migration.…”

Section: Resultsmentioning

confidence: 99%

Detecting the Origin of Cancer‐Mobile Quantum Probe for Single Cancer Stem Cell Detection

Ganesh

Venkatakrishnan

Tan

2019

Adv Funct Materials

View full text Add to dashboard Cite

Cancer stem cells (CSC) are believed to be the driving force of cancer metastases and are a rare population of self‐renewing cells that contribute majorly to the poor outcomes of cancer therapy. The detection of CSC is of utmost importance to shed light on the indestructible nature of certain solid tumors and their metastatic ability. However, tumors tend to harbor CSCs in a specialized niche, making the detection process difficult. Currently, there is no method available to detect CSCs. The significance of this work is twofold. First, to the best of the knowledge, it is the first time that the detection of CSC is demonstrated. This approach simultaneously detects both the phenotypic and the metabolic state of the cell, thus enabling universal detection of CSC with high accuracy. Second, to the best of the knowledge, for the first time, light is shed on cell chemistry of CSC in their dedicated niche to facilitate a better understanding of the key players involved in the metabolic rewiring of CSC. This work will enable a better understanding of the fundamentals of CSCs, which are critical for the early diagnosis of cancer and the development of therapies for the cure of cancer.

show abstract

“…59–61 Additionally, we included the GBM6 glioblastoma multiforme (GBM) cell line in our primary screen because it possesses a CD133 + population of cells, 62 which is a frequently used marker of GBM stem cells. 63 …”

Section: Resultsmentioning

confidence: 99%

Synthesis and antileukemic activities of C1–C10-modified parthenolide analogues

Kempema

Widen

Hexum

et al. 2015

Bioorganic & Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

Parthenolide (PTL) is a sesquiterpene lactone natural product with anti-proliferative activity to cancer cells. Selective eradication of leukemic stem cells (LSCs) over healthy hematopoietic stem cells (HSCs) by PTL has been demonstrated in previous studies, which suggests PTL and related molecules may be useful for targeting LSCs. Eradication of LSCs is required for curative therapy. Chemical optimizations of PTL to improve potency and pharmacokinetic parameters have focused largely on the α-methylene-γ-butyrolactone, which is essential for activity. Conversely, we evaluated modifications to the C1-C10 olefin and benchmarked new inhibitors to PTL with respect to inhibitory potency across a panel of cancer cell lines, ability to target drug-resistant acute myeloid leukemia (AML) cells, efficacy for inhibiting clonal growth of AML cells, toxicity to healthy bone marrow cells, and efficiency for promoting intracellular reactive oxygen species (ROS) levels. Cyclopropane 4 was found to possess less toxicity to healthy bone marrow cells, enhanced potency for the induction of cellular ROS, and similar broad-spectrum anti-proliferative activity to cancer cells in comparison to PTL.

show abstract

Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery

Cited by 18 publications

References 228 publications

Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients

Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients

Detecting the Origin of Cancer‐Mobile Quantum Probe for Single Cancer Stem Cell Detection

Synthesis and antileukemic activities of C1–C10-modified parthenolide analogues

Contact Info

Product

Resources

About